Stada Arzneimittel has made several appointments to its management team to implement a “new strategic orientation” that will see the German group focus on the ‘three pillars’ of “generics, non-prescription brands and specialty pharmaceuticals such as biosimilars” as well as expand in emerging markets (Generics bulletin, 16 March 2018, page 1). Miguel Pagan – Sandoz’ head of global technical operations and former head in Europe and India – will join Stada’s executive board with responsibility for production and development, replacing Barthold Piening. Having joined Stada from Acino midway through last year (Generics bulletin, 27 January 2017, page 16), Piening’s membership of Stada’s executive board has been cancelled with immediate effect and he “will leave Stada at the end of May 2018 in order to pursue new career opportunities”.
Meanwhile, former Sandoz executive Steffen Wagner – current managing director of Biogen Germany – will become Stada’s head of Europe...
